TAS Terms of Reference (TOR) February 2024(178 KB) - TAS
Date added: 16th May 2024
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ATOMOXETINE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents
|
| AZATHIOPRINE (UPDATED) | Orange | Dermatological disease | |
| AZATHIOPRINE (UPDATED) | Orange | Rheumatological disease | |
| CICLOSPORIN Oral (UPDATED) | Orange | Dermatological disease | |
| DAPSONE (UPDATED) | Orange | Dermatology |
See shared care agreement for details. |
| DEXAMFETAMINE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents |
| DEXAMFETAMINE (UPDATED) | Orange | Excessive sleepiness caused by narcolepsy | |
| Etrasimod (Velsipity®) (NEW) | Red | Severely active ulcerative colitis |
In line with NICE TA956 |
| GUANFACINE (UPDATED) | Orange | ADHD - Peadiatric |
Paediatric Full SCA and Request Form |
| HYDROXYCARBAMIDE (UPDATED) | Orange | Myeloproliferative disorders, sickle cell anaemia | |
| LEFLUNOMIDE (UPDATED) | Orange | Rheumatological disease | |
| LISDEXAMFETAMINE DIMESYLATE (UPDATED) | Orange | ADHD when response to methylphenidate is inadequate |
Adults Children and adolescents |
| MERCAPTOPURINE (UPDATED) | Orange | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) & Autoimmune Hepatitis | |
| METHOTREXATE Oral (UPDATED) | Orange | Rheumatological disease | |
| METHOTREXATE Oral (UPDATED) | Orange | Dermatological disease | |
| METHOTREXATE Oral (UPDATED) | Orange | Crohn's Disease | |
| METHYLPHENIDATE (UPDATED) | Orange | Excessive sleepiness caused by narcolepsy | |
| METHYLPHENIDATE (+'CR') (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care. |
| MYCOPHENOLATE MOFETIL (UPDATED) | Orange | Autoimmune conditions |
Please see shared care agreement for individual indications |
| NEFOPAM (NEW) | Red | For post-operative analgesia for patients undergoing THR / TKR |
ONLY for patients who are intolerant of NSAIDs, tramadol and/or opioids. 5 – 7 days treatment only. |
| PENICILLAMINE (UPDATED) | Orange | Rheumatoid arthritis | |
| SULFASALAZINE (UPDATED) | Orange | Rheumatological disease |
Other Updates on this Website
Recent documents from LLR APC and TAS
TAS Reference TORs February 2024(178 KB) - TAS
Date added: 15th May 2024
LLRAPC Standards for Prescribing across the NHS-Private Interface(560 KB) - Guidelines
Date added: 9th May 2024
ADHD (paediatric) SCA(903 KB) - Shared care agreement
Date added: 9th May 2024
LLRAPC Meeting Minutes April 2024(148 KB) - LMSG/LLR APC minutes
Date added: 9th May 2024
LLRAPC Newsletter – April 2024(659 KB) - LMSG/LLR APC newsletters
Date added: 1st May 2024
DAPSONE (Shared Care Request Form)(648 KB) - Shared care agreement
Date added: 1st May 2024
TAS Minutes 24th March 2024(236 KB) - TAS
Date added: 25th Apr 2024
Antimicrobial Guide for Primary Care(1 MB) - Guidelines
Version 2.3 Uploaded April 2024
Date added: 2nd May 2019
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more